ArticlePituitary2026
Hormonal staining patterns and clinical outcomes in acromegaly: a 15-year single-center study.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcromegaly is most commonly caused by pituitary somatotroph adenomas, a substantial proportion of which exhibit prolactin (PRL) expression on immunohistochemistry. However, the clinical relevance and prognostic implications of this pathological phenotype remain controversial. We aimed to compare pathological features and treatment outcomes of growth hormone/prolactin (GH/PRL)-positive adenomas with GH-only adenomas.
methodsWe retrospectively analyzed 90 patients with acromegaly who underwent transsphenoidal surgery between 2010 and 2025. Adenomas were classified according to immunohistochemical staining as GH-only, GH/PRL, or other subtypes. Clinical, biochemical, radiological, and treatment outcomes were compared across groups.
resultsOf 90 adenomas, 47 (52.2%) were GH-only, 39 (43.3%) GH/PRL, and 4 (4.4%) other PIT-1 lineage adenomas. Postoperative remission was achieved in 32 patients (35.6%), with no significant difference between GH-only and GH/PRL adenomas. In multivariable analysis, optic chiasm compression was independently associated with lower odds of remission (OR 0.212, 95% CI 0.049-0.910; p = 0.037). Among 45 patients receiving SSA therapy, 25 (55.6%) achieved biochemical response. Perinuclear CK8/18 staining (OR 4.839, 95% CI 1.198-19.540; p = 0.027) and T2-weighted MRI hypointensity (OR 5.464, 95% CI 1.284-23.250; p = 0.022) were independently associated with SSA response. Although Ki-67 was higher in GH/PRL adenomas, it was not associated with treatment outcomes.
conclusionDespite higher proliferative activity, GH/PRL adenomas did not demonstrate inferior surgical or medical outcomes compared with GH-only adenomas. Prognosis appears to be driven primarily by anatomical features and cytokeratin patterns, supporting individualized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.